

PRISMA 2020 Checklist

AI-Assisted Mammography Screening: A Systematic Review and
Meta-Analysis Completed checklist accompanying the manuscript

Section / Topic	Item	Checklist item	Location in manuscript
TITLE	1	Identify the report as a systematic review.	Title page
ABSTRACT	2	See the PRISMA 2020 for Abstracts checklist.	Structured Abstract
INTRODUCTION	3	Describe the rationale for the review in the context of existing knowledge.	Section 1.1–1.3
INTRODUCTION	4	Provide an explicit statement of the objective(s) or question(s).	Section 1.3 / Objectives
METHODS	5	Specify inclusion and exclusion criteria and how studies were grouped.	Section 2.2
METHODS	6	Specify all databases, registers, websites, organisations, reference lists searched.	Section 2.3
METHODS	7	Present the full search strategies for all databases.	Section 2.3 + Supplementary
METHODS	8	Specify methods used to decide whether a study met inclusion criteria.	Section 2.4
METHODS	9	Specify methods used to collect data from reports.	Section 2.5
METHODS	10a	List and define all outcomes for which data were sought.	Section 2.2
METHODS	10b	Specify other variables for which data were sought.	Section 2.5
METHODS	11	Specify methods used to assess risk of bias.	Section 2.6
METHODS	12	Specify effect measures used.	Section 2.7
METHODS	13a–f	Describe synthesis methods, heterogeneity, and sensitivity analyses.	Section 2.7
METHODS	14	Describe methods to assess risk of bias due to missing results.	Section 2.7
METHODS	15	Describe methods used to assess certainty of evidence.	Section 2.8
RESULTS	16a	Describe results of search and selection process; present a flow diagram.	Section 3.1, Figure 1
RESULTS	16b	Cite studies that might appear to meet criteria but were excluded.	Section 3.1
RESULTS	17	Cite each included study and present characteristics.	Section 3.2, Table 1
RESULTS	18	Present assessments of risk of bias for each study.	Section 3.3, Figure 2
RESULTS	19	Present results of all statistical syntheses.	Sections 3.4–3.7, Figures 3–5
RESULTS	20	Present results of investigations of possible causes of heterogeneity.	Section 3.8
RESULTS	21	Present results of sensitivity analyses.	Section 3.8
RESULTS	22	Present assessments of risk of bias due to missing results.	Section 3.9
RESULTS	23	Present assessments of certainty of evidence.	Section 3.10, Table 2
DISCUSSION	24a	Provide a general interpretation of results.	Section 4.1
DISCUSSION	24b	Discuss limitations of the evidence included.	Section 4.4

ON			
DISCUSSION	24c	Discuss limitations of the review processes.	Section 4.4
DISCUSSION	24d	Discuss implications for practice, policy and future research.	Sections 4.3, 4.5–4.7
OTHER	25	Provide registration information / state protocol was registered.	Section 2.1 (OSF DOI)
OTHER	26	Describe sources of financial or non-financial support.	Declarations
OTHER	27	Describe competing interests of review authors.	Declarations

This checklist follows the PRISMA 2020 statement (Page et al., BMJ 2021;372:n71). All applicable items are addressed in the manuscript locations indicated.